Back

Age differences in prescribing guideline-directed medical treatment in heart failure with mildly reduced and reduced ejection fraction

13 May 2024 (10:08 - 11:17)
Organised by: Logo
Congress Presentation Part of: ePosters in interventional cardiology and pharmacology 2 Cardiovascular Pharmacotherapy HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Vanessa Lopes

Centro Hospitalar E Universitario De Coimbra, Coimbra (Portugal)

6 More presentations in this session

Presentation thumbnail
Challenging the norm: the use of sublingual nitroglycerin in patients with severe aortic stenosis undergoing cardiac CT
Doctor A. Silva (Coimbra, PT)
Abstract Slides Video
Presentation thumbnail
Adherence to the guideline-directed medical therapy in chronic heart failure: insight from a University Hospital
Doctor M. Assamti (Oujda, MA)
Abstract Slides Video
Presentation thumbnail
Prescribing SGLT2 inhibitors in acute heart failure: considerations for dysglycemia status, heart failure phenotype, and kidney function
Doctor A. Amanova (Aktobe, KZ)
Abstract Slides Video
Presentation thumbnail
Use of SGLT2 inhibitors in real life: predicting left ventricular reverse remodelling.
Doctor V. De Simone (Legnago, IT)
Abstract Slides Video
Presentation thumbnail
Real world registry of use of SGLT2i in patients with HFrEF followed in a non-tertiary hospital.
Mr V. Martinez Mateo (Alcazar de San Juan, ES)
Abstract Slides Video

Access the full session

Session thumbnail
ePosters in interventional cardiology and pharmacology 2

The Event

Event poster

Heart Failure 2024

13 May 2024 10:08 CET
You may be interested in
thumbnail
Congress Presentation
Age-related implications in guideline-directed medical therapy up-titration for heart failure with reduced ejection fraction
thumbnail
Congress Presentation
Clinical phenotype and treatment patterns according to age in patients hospitalised for heart failure
thumbnail
Congress Presentation
Full guideline-directed medical therapy in heart failure patients with reduced ejection fraction: a real-world analysis in older patients with outcome implication

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources